Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
2
33%
Ph phase_3
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Other(1)

Detailed Status

Completed4
Active, not recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

active_not_recruiting117%
suspended117%
completed467%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_3

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT05934526
active_not_recruitingphase_2

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04816604
suspendedphase_3

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07181382
completedphase_2

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04456998
completedphase_1

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

NCT03926793
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05934526Phase 3

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Completed
NCT04816604Phase 2

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Active Not Recruiting
NCT07181382Phase 3

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Suspended
NCT04456998Phase 2

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Completed
NCT03926793Phase 1

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

Completed
NCT03473236Phase 1

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

Completed

All 6 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
6